Xu, Qin, Sharif, Maria, James, Edward, Dismorr, Jack O., Tucker, James H. R., Willcox, Benjamin E. and Mehellou, Youcef ![]() ![]() |
![]() |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (2MB) |
Abstract
The phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) is an established activator of Vγ9/Vδ2 T cells and stimulates downstream effector functions including cytotoxicity and cytokine production. In order to improve its drug-like properties, we herein report the design, synthesis, serum stability, in vitro metabolism, and biological evaluation of a new class of symmetrical phosphonodiamidate prodrugs of methylene and difluoromethylene monophosphonate derivatives of HMBPP. These prodrugs, termed phosphonodiamidate ProPAgens, were synthesized in good yields, exhibited excellent serum stability (>7 h), and their in vitro metabolism was shown to be initiated by carboxypeptidase Y. These phosphonodiamidate ProPAgens triggered potent activation of Vγ9/Vδ2 T cells, which translated into efficient Vγ9/Vδ2 T cell-mediated eradication of bladder cancer cells in vitro. Together, these findings showcase the potential of these phosphonodiamidate ProPAgens as Vγ9/Vδ2 T cell modulators that could be further developed as novel cancer immunotherapeutic agents.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy Medicines Discovery Institute (MDI) |
Additional Information: | License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/3.0/, Start Date: 2024-06-03 |
Publisher: | Royal Society of Chemistry |
ISSN: | 2632-8682 |
Date of First Compliant Deposit: | 26 June 2024 |
Date of Acceptance: | 30 May 2024 |
Last Modified: | 01 Aug 2024 13:27 |
URI: | https://orca.cardiff.ac.uk/id/eprint/170118 |
Actions (repository staff only)
![]() |
Edit Item |